Tags

Type your tag names separated by a space and hit enter

Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis.
Mult Scler. 2017 Sep; 23(10):1367-1376.MS

Abstract

BACKGROUND

Alemtuzumab was superior on clinical and magnetic resonance imaging (MRI) outcomes versus subcutaneous interferon beta-1a in phase 3 trials in patients with relapsing-remitting multiple sclerosis.

OBJECTIVE

To examine quality-of-life (QoL) outcomes in the alemtuzumab phase 3 trials.

METHODS

Patients who were treatment naive (Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis I [CARE-MS I]) or had an inadequate response to prior therapy (CARE-MS II) received annual courses of alemtuzumab 12 mg/day at baseline (5 days) and Month 12 (3 days) or subcutaneous interferon beta-1a 44 µg three times/week. QoL was measured every 6 or 12 months using Functional Assessment of Multiple Sclerosis (FAMS), European Quality of Life-5 Dimensions (EQ-5D) and its visual analog scale (EQ-VAS), and 36-Item Short-Form Survey (SF-36).

RESULTS

Statistically significant improvements from baseline with alemtuzumab were observed on all three QoL instruments at the earliest post-baseline assessment and sustained through Year 2. Statistically significant greater QoL improvements over subcutaneous interferon beta-1a were seen at all time points in CARE-MS II with FAMS, EQ-VAS and SF-36 physical component summary, and in CARE-MS I with FAMS.

CONCLUSION

Patients treated with alemtuzumab had improvements in physical, mental, and emotional QoL regardless of treatment history. Improvements were significantly greater with alemtuzumab versus subcutaneous interferon beta-1a on both disease-specific and general measures of QoL.

Authors+Show Affiliations

Department of Neurology, Hospital Universitario Quirónsalud, Madrid, Spain.Virginia Mason Hospital & Seattle Medical Center, Seattle, WA, USA.Multiple Sclerosis Center of Greater Washington, Vienna, VA, USA.MS Center, Department of Neurology, First Faculty of Medicine, Charles University, Prague, Czech Republic.Sanofi Genzyme, Cambridge, MA, USA.Sanofi Genzyme, Cambridge, MA, USA.Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.No affiliation info available

Pub Type(s)

Clinical Trial, Phase III
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

27885061

Citation

Arroyo González, Rafael, et al. "Alemtuzumab Improves Quality-of-life Outcomes Compared With Subcutaneous Interferon Beta-1a in Patients With Active Relapsing-remitting Multiple Sclerosis." Multiple Sclerosis (Houndmills, Basingstoke, England), vol. 23, no. 10, 2017, pp. 1367-1376.
Arroyo González R, Kita M, Crayton H, et al. Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis. Mult Scler. 2017;23(10):1367-1376.
Arroyo González, R., Kita, M., Crayton, H., Havrdova, E., Margolin, D. H., Lake, S. L., & Giovannoni, G. (2017). Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England), 23(10), 1367-1376. https://doi.org/10.1177/1352458516677589
Arroyo González R, et al. Alemtuzumab Improves Quality-of-life Outcomes Compared With Subcutaneous Interferon Beta-1a in Patients With Active Relapsing-remitting Multiple Sclerosis. Mult Scler. 2017;23(10):1367-1376. PubMed PMID: 27885061.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis. AU - Arroyo González,Rafael, AU - Kita,Mariko, AU - Crayton,Heidi, AU - Havrdova,Eva, AU - Margolin,David H, AU - Lake,Stephen L, AU - Giovannoni,Gavin, AU - ,, Y1 - 2016/11/25/ PY - 2016/11/26/pubmed PY - 2018/5/17/medline PY - 2016/11/26/entrez KW - Alemtuzumab KW - CD52 antigen KW - disease-modifying therapy KW - interferon beta-1a KW - multiple sclerosis KW - quality of life SP - 1367 EP - 1376 JF - Multiple sclerosis (Houndmills, Basingstoke, England) JO - Mult. Scler. VL - 23 IS - 10 N2 - BACKGROUND: Alemtuzumab was superior on clinical and magnetic resonance imaging (MRI) outcomes versus subcutaneous interferon beta-1a in phase 3 trials in patients with relapsing-remitting multiple sclerosis. OBJECTIVE: To examine quality-of-life (QoL) outcomes in the alemtuzumab phase 3 trials. METHODS: Patients who were treatment naive (Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis I [CARE-MS I]) or had an inadequate response to prior therapy (CARE-MS II) received annual courses of alemtuzumab 12 mg/day at baseline (5 days) and Month 12 (3 days) or subcutaneous interferon beta-1a 44 µg three times/week. QoL was measured every 6 or 12 months using Functional Assessment of Multiple Sclerosis (FAMS), European Quality of Life-5 Dimensions (EQ-5D) and its visual analog scale (EQ-VAS), and 36-Item Short-Form Survey (SF-36). RESULTS: Statistically significant improvements from baseline with alemtuzumab were observed on all three QoL instruments at the earliest post-baseline assessment and sustained through Year 2. Statistically significant greater QoL improvements over subcutaneous interferon beta-1a were seen at all time points in CARE-MS II with FAMS, EQ-VAS and SF-36 physical component summary, and in CARE-MS I with FAMS. CONCLUSION: Patients treated with alemtuzumab had improvements in physical, mental, and emotional QoL regardless of treatment history. Improvements were significantly greater with alemtuzumab versus subcutaneous interferon beta-1a on both disease-specific and general measures of QoL. SN - 1477-0970 UR - https://www.unboundmedicine.com/medline/citation/27885061/Alemtuzumab_improves_quality_of_life_outcomes_compared_with_subcutaneous_interferon_beta_1a_in_patients_with_active_relapsing_remitting_multiple_sclerosis_ L2 - http://journals.sagepub.com/doi/full/10.1177/1352458516677589?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -